SCHEMBL4611909

SCHEMBL4611909

O=[N+]([O-])c1ccc(OCCc2ccccc2-c2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.53
DRD4 P21917 1/20 0.53
DRD3 P35462 1/20 0.53
MAPT P10636 3/20 0.49
ALDH1A1 P00352 1/20 0.49
KCNH2 Q12809 3/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
CYP19A1 P11511 3/20 0.46
LMNA P02545 2/20 0.45
XBP1 P17861 1/20 0.45
MAPK1 P28482 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
CYP11B1 P15538 1/20 0.44
CYP11B2 P19099 1/20 0.44
PKM P14618 1/20 0.44
FFAR1 O14842 1/20 0.44
FFAR4 Q5NUL3 1/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29349920 1.00 DRD2 (0.53) DRD2DRD4DRD3MAPTALDH1A1
SCHEMBL22529979 0.85 MAPT (0.53) DRD2DRD4DRD3MAPTALDH1A1
SCHEMBL29351998 0.85 DRD2 (0.47) DRD2DRD4DRD3MAPTALDH1A1
SCHEMBL22529944 0.85 DRD2 (0.47) DRD2DRD4DRD3MAPTALDH1A1
Water SCHEMBL9770464 0.80 ALDH1A1 (0.53) MAPTALDH1A1KMT2ASMN1; SMN2FFAR1
SCHEMBL14328006 0.80 DRD2 (0.52) DRD2DRD4DRD3MAPTALDH1A1
SCHEMBL15079377 0.80 DRD2 (0.52) DRD2DRD4DRD3MAPTALDH1A1
SCHEMBL22530087 0.79 HSPB1 (0.51) DRD2DRD4DRD3MAPTALDH1A1
SCHEMBL29353486 0.79 HSPB1 (0.51) DRD2DRD4DRD3MAPTALDH1A1
SCHEMBL11292187 0.79 KCNH2 (0.61) DRD2DRD4DRD3MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113966324-A NOTCH signaling pathway inhibitors and their use in cancer treatment 塞莱斯蒂亚生物技术股份公司 2022-01-21 CN disclosed
EP-1981837-A2 METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY Praecis Pharmaceuticals Incorporated (US) 2008-10-22 EP disclosed
WO-2007092190-A2 METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY PRAECIS PHARMACEUTICALS, INC. (US) 2007-08-16 WO disclosed
EP-1781595-A1 METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY Praecis Pharmaceuticals Inc. (US) 2007-05-09 EP disclosed
WO-2006020951-A1 METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY PRAECIS PHARMACEUTICALS, INC. (US) 2006-02-23 WO disclosed